Press Release: January 17, 2019

Acquist Announces Issuance of Two U.S. Patents Covering its Drug Library of Novel Small Molecules


Press Release: November 14, 2018

Acquist Presents Positive Results for Its Lead NASH Drug, ACQT1127, at The Liver Meeting:
Central Role for Acquist Drugs that Target Lipogenesis and Inflammation



Press Release: October 2, 2018

Acquist Therapeutics to Present Scientific Results for Lead Clinical Drug in Gout



Press Release: September 25, 2018

Acquist Therapeutics to Provide Update on Lead Programs for Treating NASH and Gout


Press Release: October 11, 2017

Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout


Press Release: October 6, 2017

Relburn-Metabolomics Appoints Renowned Experts in Nonalcoholic Steatohepatitis (NASH) to its Scientific Advisory Board


Press Release: May 19, 2017

Relburn-Metabolomics Announces a Second Drug Development Program in a Highly Prevalent Liver Disease:
Company to Present at NJ BIO Partnering Conference on May 23, 2017


Press Release: October 17, 2016

Relburn-Metabolomics Files Patents on Bifunctional Nanomolar Inhibitors of Gout Target Enzymes:
Company to Present at BIO Investor Forum in San Francisco October 18, 2016


Press Release: August 1, 2016

Relburn-Metabolomics Files Fourth Patent for its Anti-Gout Drug Portfolio:
Initial Portfolio Patent Also Receives U.S. Notice of Allowance


Press Release: October 20, 2015

Relburn-Metabolomics to Outline Research Progress at BIO Investor Forum


Press Release: June 9, 2015

Relburn-Metabolomics to Present at BIO International 2015


Press Release: January 7, 2015

Relburn-Metabolomics to Present at Biotech Showcase 2015


Press Release: October 6, 2014

Relburn-Metabolomics to Report Scientific Progress and Clinical Plans for Anti-Gout Program at Two Major Conferences


Press Release: June 3, 2014

Relburn-Metabolomics to Report Clinical and Scientific Progress in Anti-Gout Program at the European Congress on Rheumatology


Press Release: January 7, 2014

Relburn-Metabolomics to Outline Clinical Development Plans for Lead Anti-Gout Product